ClinicalTrials.gg
RecruitingNCT05546528Updated Sep 21, 2023

Photobiomodulation on Major Salivary Glands in Children With Caries Activity

An interventional study of Photobiomodulation and Photobiomodulation- Sham in Caries,Dental, sponsored by University of Nove de Julho. Recruiting at 1 site in Uruguay. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by University of Nove de Julho · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

The purpose of this trial is to evaluate the efficacy of photobiomodulation of the major salivary glands on salivary parameters in children with caries activity.

Read the detailed description

Dental caries represents one of the most prevalent diseases among children around the world. Saliva plays a preponderant role in the process of demineralization- remineralization of the dental surface. Patient salivary characteristics, such as flow rate, pH, and buffering capacity, provide relevant information about patient's risk for developing carious lesions. Photobiomodulation has shown promising results to improve salivary flow rate, as well as buffer capacity in the adult population. The purpose of this trial is to evaluate the efficacy of photobiomodulation of the major salivary glands on salivary parameters in children with caries activity.

Methods: This protocol details a randomized, double-blind, parallel-group, controlled trial evaluating salivary parameters through photobiomodulation in children. Seventy-eight 6- to 12-year-old participants will be randomly divided in two groups: 1) the photobiomodulation experimental group (G1) (n=39), 2) the photobiomodulationn placebo group (G2) (n=39). Infrared light will be applied in 16 intra and extraoral points and the placebo, respectively. The unstimulated salivary sample will be taken before and immediately after the application once a week, for three consecutive weeks. Salivary samples will be analyzed for flow rate, pH and buffering capacity. The primary outcomes are difference in salivary flow rates between the G1 and the G2. The secondary outcomes are difference in salivary pH and buffering capacity between the G1 and the G2 group.

02

Conditions studied

  • Caries,Dental

Browse trials for

Keywords

  • dental caries
  • photobiomodulation
  • salivary flow
03

In context

Dental Caries

1,171 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 967 interventional studies indexed under Dental Caries.

Browse Dental Caries studies →

Lead sponsor

University of Nove de Julho is the lead sponsor of 246 studies on the registry; 52 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

nclusion criteria

  • Individuals of both sexes, between 6 and 12 years old with mixed dentition.
  • Participants diagnosed with the presence of at least one active caries lesion
  • Good general health, without systemic or local diseases that affect salivary secretions.

Exclusion criteria

  • Participants with severe active cavitated lesions with pulpal symptoms.
  • Plans of the family nucleus to move for the duration of the study.
  • Patients with a diagnosis of hyposalivation or xerostomia
  • Presence of fixed appliances.
  • Physical disability that interferes with oral or intellectual hygiene to answer the questionnaire.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    photobiomodulation

    photobiomodulation application with the Laser Therapy XT device

    Device: Photobiomodulation

  • Sham comparator
    photbiomodulation-sham

    photobiomodulation application with the Laser Therapy XT device off

    Device: Photobiomodulation- Sham

Interventions

  • DevicePhotobiomodulation

    G1 will receive the photobiomodulation application with the Laser Therapy XT device, (DMC, São Paulo, Brazil). The laser will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).

  • DevicePhotobiomodulation- Sham

    G2 will receive the photobiomodulation application with the Laser Therapy XT device off. The laser off will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).

06

What researchers measure

Primary outcomes

  1. Salivary flow

    Saliva flow rate will be estimated by asking the children to salivate into the plastic cylinders (previously weighed) for 5 minutes. Next, these plastic cylinders (containing the saliva) will be weighed and the flow rate in g/ml will be calculated, which is equivalent to ml/min,

    Time frame: three weeks

Secondary outcomes

  1. Saliva pH

    aliva pH will be measured using a previously calibrated digital pH meter

    Time frame: three weeks

07

Study locations

1 of 1 sites recruiting
  • Magdalena San-Martín
    Montevideo, Uruguay
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05546528
Responsible party
Lara Jansiski Motta (Principal Investigator, University of Nove de Julho) — Principal investigator
First posted
Sep 19, 2022
Start date
Jan 20, 2023
Primary completion
Jul 30, 2023
Completion
Nov 20, 2023 (estimated)
Last update
Sep 21, 2023

Study contacts

Lara J Motta, PhD
Contact
larajmotta@terra.com.br
11998829511
Magdalena San-Martín, MD
Contact
msanmartin@ucu.edu.uy
11998829511

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion